Printed From:

QUESTIONS ABOUT NOVEL CORONAVIRUS?
CLICK HERE.

DUPIXENT specifically targets a source of underlying inflammation in AD1

  • IL-4 and IL-13 are important in the development of Type 2 inflammation and its downstream effects1
  • DUPIXENT is a fully human monoclonal antibody for administration by subcutaneous injecton1

Learn more about how
DUPIXENT works


Watch video

DUPIXENT specifically targets IL-4 receptor, inhibiting IL-4/ IL-13 signalling1–3

  • Binds specifically to the IL-4Rα subunit shared by the receptor complexes for IL-4 and IL-131–3
  • Selectively inhibits the signalling of IL-4 via the Type 1 and 2 receptors for IL-41–3
  • Selectively inhibits IL-13 signalling via the Type 2 receptor for IL-131–3

DUPIXENT specifically targets IL-4 receptor, inhibiting IL-4/ IL-13 signalling1–3

  • Binds specifically to the IL-4Rα subunit shared by the receptor complexes for IL-4 and IL-131–3
  • Selectively inhibits the signalling of IL-4 via the Type 1 and 2 receptors for IL-41–3
  • Selectively inhibits IL-13 signalling via the Type 2 receptor for IL-131–3

DUPIXENT is a targeted immunomodulator
unlike broad spectrum immunosuppressants1

UNDERLYING TYPE 2 INFLAMMATION

AD, atopic dermatitis; IL, interleukin; ILC, innate lymphoid cells; Th, T-helper cells.

References

  1. DUPIXENT Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/8553/smpc. Date accessed: December 2020.
  2. D’Erme A, et al. Drug Des Devel Ther. 2017;11:1473–1480.
  3. McCormick M, et al. Cytokine. 2015;75(1):38–50.
  4. Guttman-Yassky E, et al. J Allergy Clin Immunol. 2019;143:155–172.